Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is
 effective in routine clinical practice for patients with epilepsy caused by a brain tumor.
Inclusion Criteria:

 -  Patient has never been treated with lacosamide (LCM) prior to this non-interventional
 study (NIS) or treatment with LCM for the first time started no earlier than 7 days
 prior to enrollment in this NIS

 -  The decision by the treating physician to prescribe LCM falls within current standard
 clinical practice, and the treatment decision is clearly separated from the decision
 to consider inclusion of the patient in the NIS

 -  A Patient Data Consent form is signed and dated by the patient and/or by the parent(s)
 or legal representative

 -  Patient is a male or female ≥ 16 years of age

 -  Patient must have a diagnosis of brain tumor-related epilepsy (BTRE) secondary to
 low-grade glioma (World Health Organization Grade 1 to 2 at time of enrollment)

 -  Patient has a retrospective Baseline seizure frequency of at least 1 partial-onset
 seizure in the 8 weeks prior to Visit 1 (enrollment/ Baseline visit)

 -  Patient does not have a previous diagnosis of epilepsy before tumor onset

 -  Patient does not have brain metastases

 -  Patient has a Karnofsky performance status scale index ≥ 60 %

 -  Patient is currently taking only 1-2 Baseline anti-epileptic drugs (AEDs) for
 epilepsy, other than LCM

 -  Patient has received a maximum of 4 different lifetime AEDs ever before entering the
 NIS

 Exclusion Criteria:

 -  N/A